Key result
Venous thromboembolism (HR 3.2; 95% CI 1.8-5.5) and pulmonary hypertension (HR 8.5; 95% CI 3.9-18.7) were associated with shorter survival in women with newly diagnosed ovarian cancer.
Why the study?
Do cardiovascular comorbidities (VTE, pulmonary hypertension) and increased baseline heart rate reduce overall survival in patients with newly diagnosed epithelial ovarian cancer?
Population
271 participants with newly diagnosed epithelial ovarian cancer
Comparison
Cardiovascular comorbidities and increased… vs Absence of these cardiovascular comorbidities or…
Design
Cohort
Follow-up
median 4.2 years
Authors
Loading...
May inform prognostic stratification in ovarian cancer; hypothesis-generating and should not yet change practice.
Cohort (n=271)
No
Do cardiovascular comorbidities (VTE, pulmonary hypertension) and increased baseline heart rate reduce overall survival in patients with newly diagnosed epithelial ovarian cancer?
Hazard Ratio: 3.2 (95% CI 1.8–5.5)
The development of venous thromboembolism and pulmonary hypertension, as well as increased baseline heart rate, are significant predictors of decreased survival in women with ovarian cancer.
Shinn et al. (2013) conducted a cohort in Epithelial ovarian cancer (n=271). Cardiovascular comorbidity (venous thromboembolism and pulmonary hypertension) vs. Absence of cardiovascular comorbidity was evaluated on Overall survival (HR 3.2, 95% CI 1.8-5.5). Venous thromboembolism (HR 3.2; 95% CI 1.8-5.5) and pulmonary hypertension (HR 8.5; 95% CI 3.9-18.7) were associated with shorter survival in women with newly diagnosed ovarian cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: